The Global Pharma industry is
undergoing huge challenges in terms of innovation and product development, as
the federal agencies are decreasing their allocation for R&D and the only
option left for the big pharma daddy's is to go for consolidation and thus
further creating non-profit
organization, which will be in place to accelerate the development of new
medicines. Last decade only we had seen TAP alliance (Takeda and Abbott) which had success story of
its own. Now the top ten pharmaceutical companies like Abbott, AstraZeneca,
Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company,
GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech a member of the Roche
Group, and Sanofi are consolidating their activity to identify and solve common
drug development challenges with the end goals of improving the quality of life
by developing novel drugs acting on Novel pathways. We Still have a ray of hope
that there will be new drugs which will help us to live better life by fighting
in and out with any sort of disease
